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Short title: 
Switching from a PI/r to  DTG regimen. 
Short summary: 
Both immediate and deferred switching from a PI/r  to a DTG regimen in virologically suppressed HIV patients ≥ 50 years 
old or with a Framingham score ≥10% was highly efficacious, well tolerated and  improved  lipid profile. 
 
Abstract 
 
Background: Both immediate or deferred switching from a PI/r to DTG may improve lipid profile. 
Methods: NEAT022 is a European, open label, randomized,  trial. HIV-infected adults ≥ 50 years or with a Framingham 
score ≥10% were eligible if HIV RNA < 50 copies/mL. Patients were randomized to switch the PI/r  to DTG immediately 
(DTG-I) or to deferred switch  at week 48 (DTG-D) . Week 96 end-points  were: proportion of patients with HIV RNA < 50 
copies/ml, percentage change of lipid fractions and adverse events. 
Results: 415 patients were randomized: 205 to DTG-I and 210 to continue PI/r plus a deferred switch (DTG-D) at week 48 . 
The primary objective of non-inferiority at week 48 was met. At week 96, treatment success rate was 92.2 % in DTG-I arm 
and 87% in DTG-D arm (difference 5.2%, 95% CI -0.6 to 11). There were 5 virological failures in the DTG-I arm and 5 (1 
while on PI/r and 4 after switching to DTG) in the DTG-D arm without selection of resistance mutations. There was no 
significant difference in terms of grade 3 or 4 AE´s or treatment modifying AE´s. Total cholesterol and other lipid fractions 
(except HDL) significantly (p<0.001) improved both after immediate and deferred switching to DTG overall   and regardless 
of baseline PI/r strata.  
Conclusions: Both immediate and deferred switching from a PI/r  to a DTG regimen in virologically suppressed HIV patients 
≥ 50 years old or with a Framingham score ≥10% was highly efficacious, well tolerated and  improved  lipid profile.  
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy505/5038116
by GlaxoSmithKline user
on 19 June 2018
  
 
Introduction: 
 
Dolutegravir (DTG) is an integrase strand transfer inhibitor (INSTI) of the HIV-1
[1-4]
 generally  well tolerated  with  
a low potential for drug-drug interactions 
[5]
,  an  infrequent emergence of  resistance mutations 
[6]
  and a  neutral 
lipid profile
[7]
 . In antiretroviral naïve patients  has demonstrated non-inferiority to raltegravir
[8]
 and bictegravir 
[9, 
10]
 and superiority  to efavirenz
[11]
 and the ritonavir boosted  darunavir
[12]
 and  atazanavir
[13]
.  
As the HIV-1 infected population ages, there is a need to identify regimens that reduce the risk of adverse 
outcomes, such as cardiovascular disease.  Dolutegravir-based regimens may be ideal for this, based on their 
efficacy and safety profile.  Raltegravir may be another choice, but there is some concern about using it as a switch 
strategy based on the SWITCHMRK  
[4]
 results.  In the STRIIVING study 
[19
, a switch of suppressed patients to 
dolutegravir was virologically non-inferior, but there was no clear benefit with respect to the lipid profile, due to 
the lower risk of the study population and the heterogeneity of the baseline regimens. From the perspective of the 
lipid profile, it may be that the evaluation of a population at higher risk of adverse outcomes and on a regimen that 
includes a boosted protease inhibitor (with a more unfavorable lipid profile) would identify a population that would 
benefit more significantly from a switch to DTG.  
 
 
We performed a randomized, non-inferiority, 96 weeks, strategic trial to compare the efficacy,  and  impact on  
lipid parameters  of  immediate switching  to DTG (DTG-I group)   to that of remaining on a PI/r regimen for first 
48 weeks 
[14]
  and then a deferred switching to DTG (DTG-D group) in a  population with potential high CVD risk.  
Methods: 
Study design and patients: 
NEAT022 was a randomized, open-label, non-inferiority trial conducted in 32 European sites (see supplementary 
Table 1). Patients were recruited between May 2014 and November 2015. Eligible patients were HIV-1-infected 
adults older than 50 years or older than 18 years with a Framingham CVD risk score 10 year risk score >10%
[15, 16]
. 
Participants had to be on a stable (>6 months) triple antiretroviral regimen consisting on a PI/r ) plus two NtRTIs 
and have a plasma HIV RNA <50 copies per mL for at least the previous 6 consecutive months. See supplementary 
table 2. 
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Ethics: 
The trial was conducted in accordance to the Good Clinical Practice and ethical principles of the declaration of 
Helsinki. The protocol was  approved by the ethics committees of all participating hospitals. All participants gave 
their written informed consent . The study was registered on ClinicalTrials.gov NCT02098837, and EudraCT 
2013-003704-39. 
 
Randomization and masking 
Eligible participants were randomly assigned  (1:1) to either switch to DTG 50mg/day plus the same two NtRTIs 
(DTG-I group)  or  to continue with the same triple therapy regimen including a PI/r for first 48 weeks 
[14]
  after 
which all patients remaining on a PI/r were switched to DTG and followed up to 96 weeks (DTG-D group) . We 
assigned patients to treatment groups by computer-generated permuted blocks of four and stratified by country.  
The study design was open-label. 
Study procedures 
Participants attended study centers at screening, baseline, weeks 4 (DTG group only), 12, 24, 36,  48, 52 (DTG-D 
group only), 60, 72, 84 and 96 weeks. Each visit included a general assessment, and collection of blood samples for 
full blood cell counts plus serum chemistry. CD4+ cell counts and plasma viral loads were measured at screening, 
baseline, weeks 24, 48, 72.and week 96. Fasting (overnight or > 6 hours) serum  lipids  were measured at all visits. 
Estimated glomerular ﬁltration rate (eGFR) was calculated by the CKD-EPI method [17].  HIV RNA measurements in 
plasma and, if indicated, testing for antiretroviral resistance by genotype sequencing were done at local laboratories 
(the local laboratories were required to meet Clinical Laboratory Improvement Amendments regulations or the 
country’s equivalent). Virological failure was defined as two consecutive measurements of plasma viral load above 50 
copies per mL separated at least by 2 weeks during the assigned treatment. A viral blip was defined by a plasma viral 
load  >50  copies of HIV RNA per mL followed by a second measurement <50 copies of  HIV RNA per mL. Safety was 
assessed at all visits by monitoring of all AEs and serious adverse events (SAEs), vital signs, and laboratory values. 
Adherence during the trial was monitored by participant questioning at each medical visit regarding missed tablets, 
at any moment during the trial or the prior week. Patients and investigators were advised not to change 
administration of lipid-lowering agents during the study period unless strictly necessary. Patients were also advised 
at each medical visit to give up smoking, to exercise daily to pay attention to their body weight, diet and alcohol 
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intake, and to control blood pressure using a written predefined healthy life style guidance formulary.  AIDS events 
and deaths, SAEs, AEs grade 3 or above, AEs leading to modification of study drugs, all protocol discontinuations 
and all protocol defined episodes of virological failures required confirmation by an independent endpoint review 
committee. 
Endpoints: 
The endpoints at 96 weeks were: 1) the proportion of patients maintaining treatment response (HIV RNA <50 
copies per mL with no discontinuation of the study treatment) and,  2) the percentage change from baseline in total 
cholesterol (TC) to week 96. Non-response was deﬁned as any of the following: virological failure, death from any 
cause, loss to follow-up, consent withdrawal or permanent change or interruption of randomized treatment for any 
reason. 
Other secondary end-points were: 1) frequency of all clinical and laboratory AEs up to week 96; 2) change in 
CD4+ cell count from baseline to week 96; 3) percentage change from baseline to week 96 of other lipid fractions: 
non-HDL cholesterol, LDL cholesterol, HDL cholesterol, triglycerides (TG) and TC:HDL cholesterol ratio and 
changes from baseline to week 96 of Framingham CVD risk score at 10 years.  
Statistical analyses: 
A total of 420 participants (210 per group) was estimated providing at least 90% power to exclude a non-inferiority 
margin of 10% for the difference in proportion of participants reaching the primary endpoint, assuming 90% of 
participants have treatment success in the DTG-D group at week 48 and a one-sided α of 0.025 (two-sided α=0.05). 
The study was powered for the first primary endpoint since this is the criterion that requires the larger sample size.  
All patients who underwent randomization were included in the intent-to-treat (ITT) population. In the primary, 
ITT analysis, the proportion of participants who had treatment success was estimated with Kaplan-Meier methods, 
censoring at week 96 or last follow-up date. The difference in percentage of participants in treatment success (DTG 
– PI/r) was estimated and two-sided 95% confidence interval (CI) of the difference was obtained with bootstrap 
standard error (1000 replicates) as proportions were estimated by time-to-event method.  
In the pre-specified sensitivity analysis on the per-protocol population, individuals were ignored if they did not 
fulfil the eligibility criteria, withdrew consent, were lost to follow-up or discontinued study medication for any 
reasons other than virological failure or adverse event. DTG-I was considered non-inferior to DTG-D if the lower 
bound of CI was below -10% for both ITT and per protocol analysis. 
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The mean percentage change from baseline in lipid fractions: TC, non-HDL cholesterol, LDL cholesterol, HDL 
cholesterol, TG and TC/HDL cholesterol ratio at week 48, the mean change from baseline in CD4+ cell counts and 
eGFR to week 48 were analyzed with the ITT population, with the last observation carried forward (LOCF) 
approach. The non-parametric Mann Whitney test was used to compare the changes from baseline between the 2 
groups.  
Subgroup analysis were also conducted to study the treatment effect by PI/r at screening (darunavir,  atazanavir, 
other PI), backbone administration of tenofovir or abacavir, Framingham 10-year CVD risk score
[15, 16]
 (<15% vs 
≥15%), and Framingham CVD  10 year risk score and age (age≤50yr and CVD risk >10%, age>50yr and CVD 
risk>10%, age>50yr and CVD risk ≤10%) for the two co-primary endpoints and all other lipid fractions. Safety 
analysis was performed with randomized patients who received at least 1 time any study treatment. Any AEs, 
grade 3 and 4 AEs, antiretroviral therapy related AEs (all grade), treatment modifying AEs (all grade), death, 
SAEs and finally AEs occurring in at least 5% of participants were described and compared by group, using 
Fisher’s exact test.  
Variables were summarized as proportions for categorical variables (based on the non-missing sample size), the 
median and interquartile range (IQR) for continuous baseline variables, and the mean and standard deviation (SD) 
for continuous variables used as endpoints. All reported p-values are two-tailed with a significance level of 0.05. 
Analyses were performed with IBM SPSS Statistics version 24 and STATA SE version 13. 
Results: 
 
 Of the 455 patients  screened  415  (ITT population) were randomized: 205 to switch to a DTG  regimen (DTG-I 
group) and 210 to continue the PI/r  regimen for 48 weeks 
[14]
 followed by a deferred switching to DTG (DTG-D 
group). See figure 1 and supplementary table 1. At least one dose of study treatment was received by 412 patients:  
204 in the DTG-I group and 208 in the DTG-D treatment group (figure 1). Baseline characteristics were balanced 
between groups (table1). 
Efficacy: 
The primary objective of non-inferiority at week 48 was met 
[14]
 (figures 2a and 2b).  At week 48, 14 patients in the 
DTG group and 10 in the PI/r group had experienced treatment failure; corresponding to a treatment success rate of 
93.1 % and 95.2 % respectively (difference -2.1%, 95% CI -6.6 to 2.4, non-inferiority demonstrated).   At week 96, 
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16 patients in the DTG-I group and 27 in the DTG-D group had experienced treatment failure; corresponding to a 
treatment success rate of 92.2% and 87%  respectively (difference 5.2%, 95% CI -0.6 to 11); Figure 2a and 
Supplementary Figure 1  . The per-protocol analysis gave a similar estimated difference of  3% (95%CI -2.3 to 
8.3); Figure 2b. Reasons for non-response were similar between groups. There were 5 protocol defined virological 
failures in the DTG-I group (plasma viral load at failures ranged from 51 to 130 HIV RNA copies per mL) and 5 
(of whom one in the first 48 weeks while receiving PI/r) in the DTG-D group (plasma viral load at failures ranged 
from 64 to 3373 HIV RNA copies per mL) with no emergent resistance associated mutations in the 3 of the 10 
samples that could be amplified (supplementary Figure 2  ). All these 10 patients but 1 reported 100%  adherence 
at all time points. Subgroup analysis can be seen in supplementary figure 3. Overall, 34 episodes of viral blips 
occurred in 33 participants (supplementary figure 2  ).  Mean increases in CD4+ cell count from baseline to week 
96 were 33±69 cells per µL in the DTG group and 14±185 cells per µL in the PI/r group (p = 0.18). 
Changes in lipids and in other CVD risk factors:  
At 96 weeks, total cholesterol and other proatherogenic lipid fractions  significantly (p<0.001) decreased from 
baseline at similar levels (p>0.05) in both the DTG-I and DTG-D groups: TC  -7.8±14.6% vs -5.8±17.7%, LDL 
cholesterol –6.9±22.0% vs -4.5±26.5%, non-HDL cholesterol –10.3±20.5% vs -8.1±23.8%, TC/HDL cholesterol 
ratio –6.4±24.4% vs -7.0%±23.1% and TG   –15.6±37.1% vs -12.1±44.1%  (Figure 3). Similar significant 
improvements were detected in both DTG-I and DTG-D  groups when analysis of lipid changes was stratified by 
baseline age and Framingham CVD risk score, by baseline PI/r  and also by backbone administration of tenofovir 
or abacavir (supplementary Figures 4a, 4b, 4c, 4d and 4e  ). The change from baseline to week 96 in the percentage 
of patients receiving lipid lowering agents, receiving or requiring
[18]
  lipid lowering agents (supplementary fig 5  ), 
currently smoking, taking daily exercise and with high blood pressure was -0.7%, -5.6%, -2.7%, 6.2% and 7.5% 
respectively in the DTG-I group and  4.3%, 0%, -4.3%, 6.7% and 0%  respectively in the DTG-D group. None of 
these changes were statistically significant. There was a trend towards a reduction in the CVD risk score at 5 years 
after 48 weeks of immediate or deferred switching to DTG using both Framingham 
[15]
 or D:A:D 
[16]
 equations 
(supplementary fig 6  ) 
Safety: 
Adverse events, all grades and causalities, were reported in 75% (weeks 0-48) and 77.9% (weeks 48-96) of the 
patients in the DTG-I arm and in 63.5% (weeks 0-48) and 83.8% (weeks 48-96) in the DTG-D arm of whom 6.4%, 
5.8% and 7.2% and 10.1% were SAE´s (p>0.05, table 2). 8 (3.9%) of patients who had received DTG in the DTG-I 
arm and 9 (4.5%) who had received DTG in the weeks 48-96 in the DTG-D arm vs. 3 (1.4%) of those who had 
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received PI/r in the weeks 0-48 in the DTG-D arm interrupted study medication due to AE. Mood disturbances or 
insomnia were the cause of DTG discontinuation in 13 of 17 patients.  The most frequent AEs occurring in ≥5% of 
patients can be seen in Table 2. A major cardiovascular event occurred in 7 patients in the  DTG-I arm   and in 8 
patients in the DTG-D arm, of whom 2 while still receiving a PI/r (Table 2).  Two death events occurred during the 
trial in the DTG-D group due to an accidental fall with a temporal bone fracture and a subdural hematoma and to a 
hepatocellular carcinoma.  
Grade 3 or 4 laboratory AEs were observed in 2.5%  (weeks 0-48) and 3.7% (weeks 48-96) of the patients in the 
DTG-I arm and in 14.9% (week 0-48 while still on PI/r) and 5.6% (weeks 48-96) in the DTG-D arm  (p<0.01 and 
p=0.47; table 2). There was also a small but significant (p<0.001) decrease in the calculated eGFR) in those who 
had received DTG    (supplementary Figure 7 ). 
Discussion: 
This is the first study to specifically examine switching from a regimen containing two NtRTIs plus a PI/r to a 
regimen with the same backbone plus DTG in virologically stable patients with high CVD risk (61% of the 
patients were both older than 50 years and with a Framingham risk score > 10%).  The primary objective of non-
inferiority at week 48 was met 
[14]
.  At 96 weeks, the study demonstrated non-inferiority for maintenance of 
control of HIV RNA in the DTG-I group  without an overall significant increase in SAEs or in any grade AEs 
related with antiretroviral therapy. Importantly in this population we showed significant reduction in 
proatherogenic lipid fractions. 
CVD is a major cause of morbidity and mortality in persons with HIV-1 infection with an estimated risk of  1.5 to 
2.0 fold higher compared  with the general population
[19]
.  Data from the D:A:D  showed that CVD accounts for  
11% of deaths among HIV-1-infected persons 
[20]
  and  the EuroSIDA study showed that cardiovascular events 
account for about one-third of non–AIDS-defining  events [21].  The US National Lipid Association [22] suggests 
that lipid goals be based on the number of risk factors   including LDL cholesterol and non-HDL cholesterol and  
HIV-1 infection may be counted as a risk factor. The  antiretroviral therapy per-se
[23-25]
 or through its effect on 
lipids should also be considered as contributing to risk of CVD
[26]
.  HIV-1 treatment guidelines recommend,  in 
addition to lifestyle changes  and lipid-lowering therapy 
[27]
,   modifications of antiretroviral regimen for  CVD 
risk reduction 
[28, 29]
. There is good evidence from the general population that reducing TC and LDL cholesterol 
reduces CVD risk
[30]
 and there is an ongoing ACTG study in HIV-1 infected patients to examine the  
cardiovascular impact of adding  pitavastatin . 
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 Switching antiretrovirals in order to improve lipid profiles can be combined with  the use of lipid lowering agents 
[3, 4, 31, 32]
.  .  TC and other proatherogenic lipid fractions  significantly  improved both after immediate and deferred 
switching to DTG  even when stratified by baseline age, Framingham risk score and baseline PI/r. Most switching 
studies have not included in the analysis non-HDL cholesterol  that  has been recently incorporated into the 
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines
[18]
.  Switching to 
DTG significantly decreased this fraction as well as TC:HDL cholesterol ratio, a factor used in some CVD risk 
equations,  which is usually unaffected in  other antiretroviral switch studies 
[4]
  
[3]
  . After switching to DTG, a 
reduction of the LDL cholesterol of  >5% (approximately 0.3 mmol per L) from baseline values was achieved. This 
level of reduction in the general population, is associated with a significant reduction in the relative risk of 
CVD
[30]
.  As 60% of study participants switched away from PI/r regimens containing  ritonavir boosted 
lopinavir
[24]
 or darunavir
[25]
  both independently   associated   with an increased CVD risk there may be an 
additional  favorable impact.  Moreover, there was a trend towards a reduction in the CVD risk scores at 5 years 
after 48 weeks of immediate or deferred switching to DTG.  A  limitation of the study  was that it was  not powered 
for differences in cardiovascular events and only 15 major cardiovascular events were observed.  
There are some risks associated with switching to a new regimen in stable  patients tolerating well the older 
medication. In our study,  virological failures were numerically more common after both immediate or deferred 
switching to DTG  (9 versus 1 while still on  PI/r) albeit all at low level and not associated with emergent 
resistance  mutations. Although there were few discontinuations, there were more after switching to DTG  (17 vs. 
3 while still on PI/r) which is often seen when patients are switching from a regimen that they have been 
tolerating from a long period of time. Of note, 13/17 discontinued due to mood disturbances or insomnia which 
have been recently highlighted 
[33, 34]
 as potential side effect of DTG. We should also recognize that switching to a 
single pill of DTG/rilpivirine or DTG/lamivudine would be more appealing in the future. Finally,  analysis of 
patient-related outcomes  was not included in the protocol that was designed more than 5 years ago. 
In conclusion, both immediate and deferred switching from a PI/r based regimen to a DTG regimen in virologically 
suppressed HIV patients aged 50 years or older or with a Framingham score ≥10% was highly efficacious well 
tolerated and significantly improved the lipid profile.  
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Figures: 
 
Figure 1: Study flow chart 
Notes: 
DTG= Dolutegravir, PI/r= ritonavir boosted protease inhibitors 
A genotypic resistance test was available in 19 (47.5%) of the 40 patients assessed for eligibility but not 
randomized. Presence of resistance mutation was the reason in 2 (5%) of these 40 patients 
 
 
Fig 2: Outcomes at 48 and 96 weeks of primary efficacy end point (Kaplan Meier estimates) 
2a) Intent-to-treat analysis  
2b) Per protocol analysis 
 
 
Fig 3: Changes in fasting lipids concentration from baseline to weeks 48 and 96 (N=415) 
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Table 1.  baseline characteristics 
 
 DTG-I (n=205) DTG-D (n=210) Total (n=415) 
Age (years) 54(51-58) 53(51-57) 54(51-58) 
Age > 50 years 179(87.3) 184(87.6) 363(87.5) 
Framingham score at 10 years    
<10% 50 (24.4) 59 (28.1) 109 (26.3) 
10-15% 62 (30.2) 53 (25.2) 115 (27.7) 
15-20% 41 (20.0) 48 (22.9) 89 (21.4) 
>20% 52 (25.4) 50 (23.8) 102 (24.6) 
Male gender 181(88.3) 189(90.0) 370(89.2) 
White race 173(84.4) 180(85.7) 353(85.1) 
Mode of HIV-1 transmission    
Male homosexual sexual intercourse 130(63.4) 131(62.4) 261(62.9) 
Heterosexual sexual intercourse 43(23.9) 48(22.9) 97(23.4) 
Other a 26(12.7) 31(14.8) 57(13.7) 
CD4+ count (cells per µL) 635(495-819) 585(471-830) 617(477-820) 
HIV RNA >50 copies per mL 7(3.4) 1(0.5) 8(2) 
Hepatitis C IgG antibodies 27(13.4) 24(11.6) 51(12.5) 
Time since undetectable viral load 
 (< 50 copies per mL); years 
4.9(2.5-9.1) 5.3(2.3-8.5) 5(2.4-8.8) 
Backbone nucleos(t)ides    
Tenofovir disoproxil fumarate/Emtricitabine 134 (65.4) 135 (64.3) 269 (64.8) 
Abacavir /Lamivudine 63 (30.7) 67 (31.9) 130 (31.3) 
Other 8 (3.9) 8 (3.8) 16 (3.9) 
PI/r at baseline       
Lopinavir 13 (6.4) 23 (11.0) 36 (8.7) 
Darunavir 105 (51.5) 109 (51.9) 212 (51.2) 
Atazanavir 77 (37.7) 72 (34.3) 151 (36.5) 
Other 9(4.4) 6(2.9) 15(3.7) 
Current Smokers 78(38.0) 79(37.8) 157(37.9) 
Diabetes mellitus 11(5.5) 13(6.3) 24(5.9) 
Family history of cardiovascular disease 87(43.3) 89(43.4) 176(43.3) 
Receiving lipid lowering agents 63(30.7) 60(28.6) 123(29.6) 
High blood pressure b 72(35.3) 79(37.6) 151(36.5) 
Daily exercise c 64(31.2) 59(28.2) 123(29.7) 
Cardiovascular risk factors d     
0 54 (26.3) 56 (26.7) 110 (26.5) 
1 71 (34.6) 63 (30.0) 134 (32.3) 
2 49 (23.9) 60 (28.6) 109 (26.3) 
≥3 31 (15.1) 31 (14.8) 47 (11.3) 
Fasting plasma lipids (mmol/L)    
Total cholesterol 5.2(4.5-5.8) 5.1(4.5-5.6) 5.1(4.5-5.7) 
Triglycerides 1.6(1.2-2.3) 1.6(1.2-2.2) 1.6(1.2-2.2) 
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Non-HDL cholesterol 3.3(2.9-4.0) 3.8(3.1-4.4) 3.8(3.2-4.5) 
LDL-cholesterol 3.1(2.5-3.7) 3.1(2.5-3.6) 3.1(2.5-3.6) 
HDL-cholesterol 1.2(1.0-1.5) 1.2(1.0-1.5) 1.2(1.0-1.5) 
Total Cholesterol/HDL cholesterol ratio 4.2(3.4-5.4) 4.1(3.4-5.2) 4.1(3.4-5.3) 
eGFR (mL/minute) 90.8(80.7-99.7) 91.4(78.3-101.8) 91.1(80-100.2) 
 
 
Data are n (%) or median (IQR) 
a 
Mode of HIV transmission was unknown in 22 (38.6 %) of the 57 and 28 ( 49.1 %) of the 57 were intravenous 
drugs users
 
b 
Defined by systolic blood pressure >140mmHg or diastolic blood pressure > 110 mmHg or receiving anti-
hypertensive treatment addition
 
c 
Defined as self-reported some exercise (duration not specified) every day 
 
d 
An addition of male patients with age more than 50 years or female patients with age more than 60 years, current 
or past smoker within the last 3 years, HDL cholesterol less than 1 mmol/L, high blood pressure, diabetes mellitus, 
family history of cardiovascular diseases. HDL cholesterol levels above 1.5 mmol/L, implicates a subtraction of 
one risk factor. 
 
 eGFR=estimated glomerular filtration rate (CKD-EPI method). DTG-D= Dolutegravir-deferred. DTG-I= 
Dolutegravir-immediate 
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Table 2: Adverse events in 412 patients who received either dolutegravir (n=204) or ritonavir boosted protease 
inhibitor (n=208).  
 
 DTG-I arm 
 
DTG-D arm 
 
  
  
0-48 weeks 
(n=204) 
 
48-96 weeks 
(n=190) 
 
0-48 weeks
a
 
(n=208) 
 
48-96 weeks 
(n=198) 
P value 
 
0-48 
weeks 
P value 
 
48-96 
weeks 
 Patients 
n(%) 
Adverse 
events 
(n) 
Patients 
n(%) 
Adverse 
events 
(n) 
Patients 
n(%) 
Adverse 
events 
(n) 
Patients 
n(%) 
Adverse 
events 
(n) 
  
Summary of adverse 
events 
          
Any adverse event 153 (75.0) 395 148 (77.9) 416 132 (63.5) 352 166 (83.8) 558 0.014 0.156 
Grade 3 or 4 adverse 
events 
12 (5.9) 17 13 (6.8) 18 18 (8.7) 31 21 (10.6) 34 0.344 0.212 
Serious adverse events 13 (6.4) 14 11 (5.8) 15 15 (7.2) 27 20 (10.1) 28 0.845 0.136 
Discontinuation due to 
adverse events 
8 (3.9)
 b
 
8 0 (0.0) 0 
3 (1.4)
 c
  
3 
9 (4.5)
 b
 
9 0.137 0.004 
Any adverse event 
related to antiretroviral 
therapy 
25 (12.3)
 d
 
40 
15 (7.9)
 d
 
20 
14 (6.7)
 e
 
20
 
 
42 (21.2)
 d
 
74 0.064 <0.001 
Death 0 (0.0)  0 (0.0)  
1 (0.5)
 f
 
 
1 (0.5)
 f
 
 1.000 1.000 
Adverse events, any 
grade, occurring in at 
least 5% of patients in 
either group 
          
Digestive 41 (20.1) 52 36 (18.9) 50 37 (17.8) 54 56 (28.3) 89 0.615 0.032 
Muscular or skeletal 49 (24.0) 63 50 (26.2) 82 40 (19.2) 52 66 (33.3) 102 0.281 0.150 
Cardiovascular 
10 (4.9)
 g
 
12
 
 
19 (10.0)
 g
 
27
 
 
18 (8.7)
 g
 
20 
18 (9.1)
 g
 
22
 
 0.170 0.863 
Respiratory 63 (30.9) 90 53 (27.9) 67 49 (23.6) 65 61 (30.8) 80 0.098 0.578 
Dermatological 36 (17.6) 43 46 (24.2) 61 27 (13.0) 38 53 (26.8) 77 0.218 0.641 
Genitourinary 32 (15.7) 37 25 (13.2) 30 14 (6.7) 26 28 (14.1) 41 0.005 0.883 
Systemic 26 (12.7) 28 27 (14.2) 31 35 (16.8) 43 42 (21.1) 55 0.269 0.084 
Neuropsychiatric 43 (21.1) 63 39 (20.5) 49 36 (17.3) 46 51 (25.8) 69 0.381 0.231 
Grade 3 or 4 laboratory 
adverse events 
          
Any grade 3 or 4 
laboratory adverse event 
5 (2.5) 10 7 (3.7) 7 31 (14.9) 55 11 (5.6) 12 <0.001 0.472 
Alanine 
aminotransferase 
concentration >5xULN 
1 (0.5) 1 0 (0.0) 0 1 (0.5) 1 1 (0.5) 1 1.000 1.000 
Bilirubin >2.5xULN 2 (1.0) 4 0 (0.0) 0 16 (7.7) 28 1 (0.5) 1 0.001 1.000 
LDL cholesterol >4.9 
mmol/L 
3 (1.5) 5 3 (1.6) 3 15 (7.2) 22 5 (2.5) 6 0.006 0.724 
 
Data are number of patients (%) or number of events. 
 DTG-I=Dolutegravir immediate group. DTG-D= Dolutegravir-deferred group.  
P-value: comparison of proportion of patients with at least one adverse event between all DTG groups vs. ritonavir boosted protease inhibitors 
a)  During the period 0-48 weeks patients of the DTG-D arm were receiving a ritonavir boosted protease inhibitor 
b)  1 case each of acute hepatitis C, chest pain and fatige, rash and poor control of diabetes and 13 cases of mood and/or sleep disorders 
c) 1 case each of hepatitis C,  dyspepsia and  declining renal function 
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d) mood and/or sleep disorders in 27 (33%) of the 87 patients who developed adverse events related with antiretroviral therapy while on DTG 
e) mood and/or sleep disorders in 5 (36%) of the 14 patients who developed adverse events related with antiretroviral therapy while on PI/r 
 f) One case each of an accidental fall with a temporal bone fracture and subdural hematoma and an hepatocellular carcinoma 
g)  1/10, 6/19, 2/18, 6/18 patients respectively developed a major cardiovascular  event 
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Figure 2a. 
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Figure 2b. 
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Figure 3. 
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